Documentation is the underwriting

In most insurance classes, underwriting is about revenue and loss history. In the peptide class, it is about documentation. Carriers are trying to answer one question: does this business behave like a research supplier, or does it behave like a consumer product company wearing a research label?

Three documents answer that question faster than any application.

1. Certificates of analysis

A certificate of analysis should identify the compound, the batch or lot, the testing laboratory, the methods used, and the results, including purity and any relevant contaminants. Carriers look for:

  • Testing from an accredited third-party laboratory rather than an in-house sheet
  • Batch-level traceability, so a specific vial maps to a specific COA
  • Consistency across products, not one good COA and ten missing ones
  • Dates that line up with the shipment records

A partial COA package is not an automatic decline, but it usually produces a higher premium, a higher deductible, or an exclusion for the undocumented products.

2. Label artwork

The label is where the research use only position either holds together or falls apart. What underwriters check:

  • The RUO statement is present and legible on the actual artwork
  • No dosing, administration, or human-use language appears anywhere on the label
  • No before-and-after imagery, body imagery, or outcome claims
  • Lot number and storage instructions are present
  • The label matches what the website says about the product

An RUO statement printed on a label that also carries a dosing suggestion is worse than no statement at all, because it documents that the business knew the intended use.

3. Website and checkout flow

The site is the document carriers read most carefully, because it is where intent shows. What helps:

  • Product pages that describe research context rather than outcomes
  • A click-to-accept research use certification at checkout
  • Buyer verification, such as business registration or institutional email screening
  • No human-use testimonials, no dosing calculators, no "protocol" guides
  • Terms of sale that state the research use restriction and the buyer's responsibility

What hurts: a blog post about results, a FAQ answering "how much should I take," or a testimonial about someone's experience. Any of these converts a defensible RUO position into a documented inconsistency.

Keeping the three aligned

The practical test is simple. Take one product. Compare the COA, the label, and the product page. If all three describe the same thing in the same terms, the file is clean. If any one of them drifts toward human use, that is the gap an underwriter will find and a claimant's attorney will use.

Run that test quarterly, and again after any website update. Most documentation failures arrive through a marketing change, not through a manufacturing change.

What to send with an application

  • COA package by product
  • Label artwork
  • Website URL and checkout screenshots
  • Buyer verification description
  • Product list with revenue concentration
  • Prior claims, recalls, and chargebacks

Accounts that send all six in the first message usually move to a quote without a second round of questions.

Next step

The tier structure and the full underwriting checklist are on the RUO peptide insurance hub. To review your own documentation, request a peptide quote and include your COA package and site link.

This article is general information, not a quote or an offer of coverage. Coverage decisions rest with the carrier after underwriting review.